InstalabLoading...
InstalabLoading...
Most adults walk around carrying a virus they have never heard of. CMV (cytomegalovirus) infects 60 to 90% of people globally, settles into the body for life, and usually causes no symptoms at all. Yet research increasingly links carrying CMV to faster immune aging, complications in pregnancy, and worse outcomes after transplant or critical illness.
This blood test checks two antibodies your immune system makes against CMV: IgG (immunoglobulin G), which signals past infection, and IgM (immunoglobulin M), which suggests recent or active infection. Knowing your status answers a specific question almost no one asks: have you been exposed to a virus that may be quietly influencing your long-term health?
CMV antibody testing is not a measure of how much virus is in your body. It measures the antibodies your immune system has produced in response to the virus, and the pattern of those antibodies tells a story about timing.
Once you become IgG positive, you stay positive for life. The virus settles into immune cells and your body keeps a steady supply of antibodies on patrol. The level of those antibodies, called the titer, can rise during periods of reactivation, which is why repeat testing matters.
The link between CMV and cardiovascular disease has been studied for years, with mixed results that depend heavily on the population studied. A meta-analysis of prospective studies found that CMV seropositivity was associated with a meaningfully higher risk of ischemic heart disease, stroke, and cardiovascular death, with the authors estimating that 13.4% of cardiovascular disease incidence may be attributable to CMV.
Among people aged 85 and older in the Newcastle 85+ study, CMV seropositivity combined with T-cell senescence (a sign of an exhausted immune system) predicted increased cardiovascular mortality. CMV IgG titers have also been linked to long-term inflammation and the prevalence of cardiovascular and metabolic diseases in a large European aging cohort.
Other large studies tell a quieter story. A meta-analysis across multiple cohorts of community-dwelling older white adults found no association between CMV and all-cause or cardiovascular mortality. A UK Biobank analysis using acyclic graphs reached a similar conclusion in a younger general population. The most likely explanation is that CMV is not a uniform risk factor for everyone. Its cardiovascular signal becomes visible mostly in older adults, in people with HIV or other inflammatory conditions, and in cohorts where ethnic and socioeconomic factors concentrate higher antibody titers and chronic inflammation. CMV is best read as one input into a larger immune aging picture, not a stand-alone heart attack predictor.
CMV is the single biggest known driver of changes in the aging immune system. Over decades, the body devotes a growing share of its T cells to keeping CMV in check, and those T cells take on features of senescence, meaning they look and behave older. In a study of 247 adults across the lifespan, anti-CMV antibody levels stratified people into distinct immune profiles, with higher antibody levels tracking with markers of inflammation and immune remodeling. Among elderly Latinos followed for nine years, higher CMV IgG levels were associated with increased mortality, with inflammatory markers like interleukin-6 (a signaling protein released during inflammation) and tumor necrosis factor partly mediating the link.
In a cohort of older Black and white adults, CMV infection was associated with higher Alzheimer disease risk and faster cognitive decline. CMV antibodies in blood have also been linked to mood disorders, suicide, and markers of brain inflammation and microglia activation (immune cells inside the brain) found in postmortem brain tissue. These findings do not prove that CMV causes cognitive or psychiatric disease, but they suggest the virus may sit closer to the brain than its usually silent presence implies.
CMV is the most common congenital infection. Between 0.64% and 1% of all births involve congenital CMV, and 10 to 20% of those affected children develop serious long-term consequences such as hearing loss or developmental delay. Knowing your IgG status before or early in pregnancy is genuinely actionable: if you are seronegative, simple hygiene measures (especially around young children's saliva and urine) reduce your risk of catching CMV when the consequences for the fetus are highest.
If you are heading toward a transplant, on immune-suppressing therapy, or living with HIV, CMV status changes how you are managed. The highest-risk pattern in solid organ transplant is a CMV-negative recipient receiving an organ from a CMV-positive donor (D+/R-), where reactivation can drive serious illness. Among hematopoietic stem cell transplant recipients, CMV viremia after transplant is associated with higher overall mortality in the first year. CMV reactivation is also common in critically ill patients in the intensive care unit and in people on systemic corticosteroids or strong immunosuppressants, where it has been linked to more organ dysfunction.
CMV antibodies are reported as positive, negative, or sometimes equivocal. Cutoff values vary slightly between labs, and IgM assays in particular can give different answers depending on the platform. Compare results within the same lab over time for the most meaningful trend.
| Result Pattern | What It Suggests | What to Do Next |
|---|---|---|
| IgG negative, IgM negative | No prior CMV infection. You are susceptible to primary infection. | If pregnant or trying to conceive, focus on hygiene measures around young children. Retest if symptoms develop. |
| IgG positive, IgM negative | Past infection. The virus is in your body in a latent state. | No immediate action. Track titer trends if you have inflammatory or aging concerns. |
| IgG positive, IgM positive | Possible recent or reactivated infection. False positives are common. | Confirm with an IgG avidity test. Low avidity suggests recent primary infection. |
| IgG negative, IgM positive | Possible very early primary infection or false positive. | Repeat testing in 2 to 4 weeks and consider CMV PCR (a test that detects viral DNA directly). |
Note: a positive IgM result alone is one of the most commonly misinterpreted findings in clinical medicine. In a multi-hospital study of immunocompetent adults hospitalized with mononucleosis-like illness, dual CMV and EBV (Epstein-Barr virus) IgM positivity, limited DNA testing, and absence of avidity testing made misclassification routine. Avidity testing, which measures how tightly antibodies bind the virus, is the standard way to tell a recent primary infection from a long-past one.
Once you are IgG positive, the binary positive or negative result will not change. What can change is the IgG titer, which reflects how actively your immune system is engaging with the virus. Higher titers have been associated with worse cardiovascular and mortality outcomes in older adults, and titer changes over years can offer a window into immune aging that a single reading cannot.
If you are seronegative, retesting matters most during pregnancy and in any period of new high-exposure contact (a job change involving young children, a new caregiver role). If you are seropositive, an annual or biennial titer measurement gives you a trend line. If you are immunocompromised or on immunosuppressive therapy, your provider will typically pair antibody testing with CMV PCR to track active replication directly.
An unexpected positive IgM should prompt three things: an IgG avidity test to date the infection, a CMV PCR to look for active viral DNA in blood, and a careful review of any recent illnesses or new medications. If you are pregnant and IgM positive with low IgG avidity, that pattern raises concern for recent primary infection and warrants specialist input from maternal-fetal medicine. If you are seronegative going into a transplant where the donor is seropositive, your transplant team will plan antiviral prophylaxis or pre-emptive monitoring. If you are simply IgG positive with rising titers and no obvious illness, that pattern is worth pairing with markers of inflammation and immune aging rather than acting on in isolation.
Companion tests that add the most context: hs-CRP (high-sensitivity C-reactive protein, a general inflammation marker), a complete T-cell panel including CD4 and CD8 counts, and EBV antibodies for comparison since the two viruses overlap in their effects on the aging immune system.
Evidence-backed interventions that affect your Cytomegalovirus level
Cytomegalovirus is best interpreted alongside these tests.